ClinicalTrials.Veeva

Menu

Liver Transplantation for Non-Resectable Colorectal Liver Metastasis

S

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status

Enrolling

Conditions

Liver Metastasis Colon Cancer
Colorectal Cancer

Treatments

Procedure: Liver Transplantation

Study type

Interventional

Funder types

Other

Identifiers

NCT05185245
LITORALE2020

Details and patient eligibility

About

The study aims to evaluate the efficacy of liver transplantation in the context of non-resectable colorectal liver metastasis. The primary endpoint is the overall survival in this group of patients while the secondary endpoint is the disease-free survival.

Patients included in this protocol will be evaluated either for whole or partial liver transplantation from deceased or living donors.

Type of different transplantations proposed are as follows:

  1. Whole liver graft or partial liver (split) from a deceased donor
  2. Partial liver graft retrieved from a deceased donor and orthotopically implanted after having performed a left hepatectomy in the recipient.
  3. Partial liver graft retrieved from a deceased donor and heterotopically implanted if total hepatectomy can not be performed.
  4. Partial liver graft retrieved from a living donor and orthotopically implanted after having performed total hepatectomy.
  5. Partial liver graft retrieved from a living donor and orthotopically implanted after having after having performed a left hepatectomy in the recipient.
  6. Partial liver graft retrieved from a living donor and heterotopically implanted if total hepatectomy can not be performed.

In cases 2-3-5-6 total hepatectomy of native liver can be secondarily performed after having achieved a proper graft hypertrophy in order to avoid a small for size syndrome

Enrollment

20 estimated patients

Sex

All

Ages

18 to 73 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Primary tumor resected according to standard oncological practice, p≤T4a, R0 resection
  • Colorectal liver metastasis considered as non-resectable either up-front or after previous hepatic resections
  • No local recurrence of primary colon cancer confirmed by Positron Emission Tomography, Computed Tomography and colonoscopy
  • No extra-hepatic metastatic disease confirmed by Positron Emission Tomography and Computed Tomography
  • Good performance status Eastern Cooperative Oncology Group 0 or 1
  • Neutrophils > 1.000
  • Patients who received at least one line of chemotherapy for at least 3 months with partial response or stable disease according to modified Response Evaluation Criteria in Solid Tumours
  • Carcino-Embryonic Antigen < 80 µg/L or reduction of ≥ 50% of highest Carcino-Embryonic Antigen level observed
  • Written informed consent
  • No other contraindications to liver transplantation

Exclusion criteria

  • Presence of other malignancies
  • Local recurrence of primary tumor
  • Extra-hepatic metastatic disease
  • Patients who did not receive any neoadjuvant or adjuvant therapy
  • Palliative resection of primary tumor
  • Any other reason, according to the investigators, that could be a contraindication to protocol enrollment

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Liver Transplantation
Experimental group
Treatment:
Procedure: Liver Transplantation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems